Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478692 | 1.00 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL7692832 | 0.95 | OPRK1 (0.91) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17873667 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6OPRD1 | |
| SCHEMBL17873664 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6OPRD1 | |
| SCHEMBL9510585 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL5629426 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6479102 | 0.88 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6479105 | 0.88 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6597247 | 0.88 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17873646 | 0.86 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | claimed |
| EP-1112252-A4 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORP (US) | 2004-07-14 | — | — | EP | claimed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | claimed |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-01-31 | — | — | US | claimed |
| EP-1112252-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | Adolor Corporation (US) | 2001-07-04 | — | — | EP | claimed |
| US-6239154-B1 | ARYLACETAMIDES, AGONISTS AT KAPPA OPIOID RECEPTORS. | ADOLOR CORPORATION | 2001-05-29 | — | — | US | claimed |
| WO-2000014065-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 2000-03-16 | — | — | WO | claimed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6492351-B1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-6476063-B2 | DEVOID OF CENTRAL NERVOUS SYSTEM EFFECTS; TOPICAL AND SYSTEMIC ADMINISTRATION; ANTIPRURITIC AGEENTS; ANALGESICS 1-ARYLMETHYLCARBONYL-2-PYRROLIDIN-1-YL-PIPERAZINES | ADOLOR CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-6391910-B1 | OPIOID ANTAGONIST; ANALGESIC | ADOLOR CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-6303611-B1 | FOR THERAPY OF HYPERALGESIS | ADOLOR CORPORATION | 2001-10-16 | — | — | US | disclosed |
| US-6239154-B1 | ARYLACETAMIDES, AGONISTS AT KAPPA OPIOID RECEPTORS. | ADOLOR CORPORATION | 2001-05-29 | — | — | US | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | OPRK1 1/4885CYP2D6 1292/4885CYP3A4 880/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 659/4885CYP3A4 505/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 541/4885CYP3A4 304/4885 |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | OPRK1 1/4885CYP2D6 1292/4885CYP3A4 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.